How should antiphospholipid syndrome be diagnosed and managed in patients presenting with unexplained deep‑vein thrombosis, pulmonary embolism, stroke, myocardial infarction, or recurrent fetal loss?

Diagnosis and Management of Antiphospholipid Syndrome

Diagnostic Criteria

Antiphospholipid syndrome requires BOTH persistent laboratory positivity AND clinical manifestations—neither alone is sufficient for diagnosis. 1

Laboratory Criteria

• Test for all three antiphospholipid antibodies: lupus anticoagulant (LAC), anticardiolipin antibodies (aCL IgG/IgM), and anti-β2-glycoprotein-I antibodies (aβ2GPI IgG/IgM). 1
• Antibodies must be positive on two separate occasions at least 12 weeks apart to confirm persistence and exclude transient positivity. 1
• Moderate-to-high titers are defined as ≥40 Units (moderate) or ≥80 Units (high) for aCL and aβ2GPI. 1
• Lupus anticoagulant is the strongest predictor of adverse outcomes, with a relative risk of approximately 12 for pregnancy complications. 1
• Triple positivity (all three antibodies positive) confers the highest thrombotic risk and mandates the most aggressive management. 1

Clinical Criteria

• Thrombotic events: Arterial (stroke, myocardial infarction) or venous (deep-vein thrombosis, pulmonary embolism) thrombosis in any vascular bed. 1, 2
• Pregnancy morbidity: ≥3 consecutive early pregnancy losses (<10 weeks), ≥1 unexplained fetal death (≥10 weeks), or ≥1 premature birth (<34 weeks) due to severe preeclampsia, eclampsia, or placental insufficiency. 1

When to Test

• Test in patients with unexplained thrombosis (especially age <50 years), recurrent pregnancy loss, or cryptogenic stroke with history of thrombosis or rheumatologic disease. 1, 3
• Do NOT systematically screen older adults with conventional vascular risk factors—evidence does not support routine testing in this population. 1

---

Management of Thrombotic APS

Venous Thromboembolism (DVT/PE)

Lifelong warfarin targeting INR 2.0–3.0 is the gold standard for venous thrombotic APS. 4, 1

• Initiate with parenteral anticoagulation (low-molecular-weight heparin preferred) overlapping with warfarin until therapeutic INR is achieved for at least 24 hours. 5
• Monitor INR at least monthly; more frequent testing if unstable. 1
• Never discontinue anticoagulation—recurrence risk is extremely high without lifelong therapy. 1, 6

Arterial Thrombosis (Stroke, MI)

For arterial events, choose one of two evidence-based regimens: 1

1. High-intensity warfarin (INR 3.0–4.0), OR
2. Moderate-intensity warfarin (INR 2.0–3.0) PLUS low-dose aspirin 81 mg daily

• The 2021 AHA/ASA guidelines favor moderate-intensity warfarin (INR 2.0–3.0) over higher targets to balance thrombosis prevention against bleeding risk. 4
• Arterial APS carries higher recurrence risk than venous APS, justifying more aggressive strategies. 1

Direct Oral Anticoagulants (DOACs)

Rivaroxaban and all DOACs are contraindicated (Class III: Harm) in APS, especially triple-positive patients. 4, 1

• Rivaroxaban is associated with excess recurrent arterial thrombotic events compared with warfarin in triple-positive APS. 4
• Observational data confirm high recurrence rates with all DOACs in APS. 4
• If a patient is already on a DOAC, transition immediately to warfarin. 1

Isolated Antiphospholipid Antibodies Without Full APS Criteria

Antiplatelet therapy alone (aspirin 81–325 mg daily) is recommended for patients with isolated positive antibodies who do not meet full APS criteria. 4, 3

• The WARSS/APASS trial showed no benefit of warfarin over aspirin in this population (warfarin RR 0.99,95% CI 0.75–1.13; aspirin RR 0.94,95% CI 0.70–1.28). 3, 5
• This applies to patients with cryptogenic stroke and isolated antibody positivity. 4, 3

---

Management of Obstetric APS

Confirmed Obstetric APS (≥3 Early Losses or ≥1 Late Loss)

Combined low-dose aspirin (81–100 mg daily) PLUS prophylactic-dose low-molecular-weight heparin throughout pregnancy is strongly recommended. 1

• Aspirin should be started before 16 weeks gestation and continued through delivery. 1
• Prophylactic LMWH dosing: enoxaparin 40 mg SC daily or dalteparin 5,000 U SC daily. 1
• Continue LMWH for 6–12 weeks postpartum to cover the heightened post-delivery thrombotic period. 1
• This regimen achieves approximately 70% live-birth rates. 1

Thrombotic APS in Pregnancy

Therapeutic-dose LMWH (enoxaparin 1 mg/kg SC twice daily) PLUS low-dose aspirin throughout pregnancy and postpartum is required. 1

• This applies to women with prior APS-related thrombotic events. 1
• Maintain therapeutic anticoagulation for at least 6–12 weeks after delivery. 1

Asymptomatic Antiphospholipid Antibody-Positive Pregnant Women

Low-dose aspirin 81–100 mg daily alone is advised, started before 16 weeks and continued through delivery. 1

• Routine prophylactic LMWH is NOT recommended unless very high-risk features are present: triple-positive antibodies, strongly positive lupus anticoagulant, advanced maternal age, or IVF conception. 1

Adjunctive Therapy

• Hydroxychloroquine 200–400 mg daily may be added to standard therapy for primary APS; small studies suggest fewer pregnancy complications. 1
• Hydroxychloroquine should be continued throughout pregnancy in patients with concurrent systemic lupus erythematosus. 1

Pregnancy Monitoring Protocol

• Monthly clinical assessments with rheumatology or high-risk obstetrics. 1
• Blood pressure at every visit—preeclampsia occurs 2.3-fold more often in APS. 1
• Serial fetal ultrasounds with Doppler starting at 16–20 weeks, then monthly in third trimester. 1
• Laboratory monitoring: complete blood count, urinalysis with protein-to-creatinine ratio, serum creatinine, and complement C3/C4 at least once per trimester. 1
• Increase surveillance to every 1–2 weeks after 32 weeks or sooner if abnormalities detected. 1

---

Primary Prevention in Asymptomatic Carriers

Low-dose aspirin 75–100 mg daily is strongly recommended for asymptomatic patients with high-risk antibody profiles (triple-positive, double-positive, isolated lupus anticoagulant, or persistently high-titer aCL). 1

• This applies to patients with no prior thrombosis. 1
• The same regimen applies to SLE patients with high-risk antibody profiles to reduce stroke risk. 1
• For low-risk profiles (isolated aCL or aβ2GPI at low-to-medium titers), aspirin may be considered after clinician-patient discussion. 1
• Aggressive cardiovascular risk-factor modification—smoking cessation, blood pressure control, lipid management—is essential in all asymptomatic carriers. 1

---

Catastrophic Antiphospholipid Syndrome

Catastrophic APS requires immediate triple therapy: anticoagulation, high-dose glucocorticoids, and plasma exchange. 1

• Immediate therapeutic anticoagulation with unfractionated heparin or LMWH. 1
• High-dose IV glucocorticoids: methylprednisolone 500–1,000 mg daily for 3–5 days, followed by oral prednisone 1 mg/kg/day. 1
• Plasma exchange is associated with improved survival in retrospective studies and should be initiated promptly. 1
• Add IV cyclophosphamide if catastrophic APS occurs in the setting of SLE flare (500–1,000 mg/m² monthly). 1
• Rituximab or eculizumab (complement C5 inhibitor) may be considered for refractory cases. 1

---

Special Populations and Situations

Contraception in Women with Antiphospholipid Antibodies

• Intrauterine devices (IUDs) are preferred, or progestin-only pills. 5
• Combined estrogen-progestin contraceptives are contraindicated due to increased thrombotic risk. 5

Assisted Reproductive Technology (ART)

• Defer ART if disease is moderately or severely active. 1
• For obstetric APS undergoing ART: prophylactic LMWH starting at ovarian stimulation, withheld 24–36 hours before oocyte retrieval, resumed after retrieval. 1
• For thrombotic APS undergoing ART: therapeutic anticoagulation throughout. 1

Renal Transplant Candidates

• Delay transplantation until lupus activity is absent or low for 3–6 months. 1
• Peri-operative anticoagulation is required for patients with moderate-to-high antibody titers. 1

APS with Sepsis

• Continue therapeutic warfarin (INR 2.0–3.0) unless active bleeding or specific contraindication. 1
• Sepsis is prothrombotic and may synergize with APS thrombotic risk, making anticoagulation critical. 1
• Do not withhold anticoagulation based on thrombocytopenia alone unless platelet count is critically low or active bleeding is present. 1

---

Common Pitfalls and Caveats

• Do not diagnose APS based on a single positive test—persistence at ≥12 weeks is mandatory. 1
• Do not use DOACs in any APS patient, especially triple-positive or arterial disease—this is associated with treatment failure. 4, 1
• Do not assume isolated antibody positivity equals APS—clinical criteria (thrombosis or pregnancy morbidity) are required. 4, 3
• Do not test for protein C, protein S, or antithrombin during acute stroke—these levels are altered by the acute event; defer testing 4–6 weeks (up to 6 months for factor VIII). 3
• Lupus anticoagulant may interfere with INR determination—consider anti-Xa monitoring in selected patients. 5
• Do not discontinue aspirin before delivery solely for anesthesia concerns—aspirin does not typically complicate delivery. 1
• Do not rely solely on umbilical-artery Doppler after 34 weeks—incorporate cerebro-placental ratio and abdominal-circumference growth velocity. 1